Anti-Human FOLR1 Reference Antibody (Luveltamab, RUO) (HB825036)

Datasheet Share product Copy info

Price(USD): $

Spec:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Number:

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HB825036
Description	Luveltamab (HB825036) is a research-grade recombinant antibody targeting Folate receptor alpha. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Humanized
Isotype	IgG1-kappa
Expression system	Mammalian Cells
Clonality	Monoclonal
Target	Folate receptor alpha, FOLR, FOLR1, Adult folate-binding protein, Folate receptor 1, FR-alpha, KB cells FBP, FBP, Ovarian tumor-associated antigen MOv18, Folate receptor, adult
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P15328
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	SP8193, STRO002, STRO-002, 2493327-59-4
Background	Folate receptor alpha (FOLR1) is a ~29 kDa protein. Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate and folate analogs into the interior of cells. Has high affinity for folate and folic acid analogs at neutral pH. Exposure to slightly acidic pH after receptor endocytosis triggers a conformation change that strongly reduces its affinity for folates and mediates their release. Required for normal embryonic development and normal cell proliferation. FOLR1 is the therapeutic target of mirvetuximab soravtansine (Elahere). 1. Zhao, R. et al. (2009) The Journal of biological chemistry 284, 4267-74. PMID: 19074442 2. Chen, C. et al. (2013) Nature 500, 486-9. PMID: 23851396 3. Wibowo, AS. et al. (2013) Proceedings of the National Academy of Sciences of the United States of America 110, 15180-8. PMID: 23934049 4. Lacey, SW. et al. (1989) The Journal of clinical investigation 84, 715-20. PMID: 2527252 5. Orr, RB. et al. (1994) Cancer research 54, 3905-11. PMID: 8033114 6. Rijnboutt, S. et al. (1996) The Journal of cell biology 132, 35-47. PMID: 8567728
Note	For research use only. Not suitable for clinical or therapeutic use.

Images

SDS-PAGE

SDS-PAGE for Research Grade Luveltamab.
Bioactivity

Detects recombinant FOLR1 (Catalog No: HB825011) in indirect ELISA.

References

Datasheet

Anti-Human FOLR1 Reference Antibody (Luveltamab, RUO).pdf

Download SDS PDF

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

Concentration

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

V₁ (Stock Vol.)

Working Solution

C₂ (Working Conc.)

V₂ (Working Vol.)

Recombinant Proteins

Antibodies

Assay Kits

Anti-Human FOLR1 Reference Antibody (Luveltamab, RUO) (HB825036)

Overview

Images

References

Datasheet

SDS

Quick access

Contact Us